Next-Generation Extracorporeal Blood Treatment System

Publication ID: 24-11857715_0010_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Next-Generation Extracorporeal Blood Treatment System,” Published Technical Disclosure No. 24-11857715_0010_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857715_0010_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,715.

Summary of the Inventive Concept

A wearable, implantable, or minimally invasive blood treatment system integrating micro-robotic navigation, artificial intelligence, and blockchain technology to revolutionize extracorporeal blood treatment.

Background and Problem Solved

The original patent's extracorporeal blood treatment apparatus, while effective, has limitations in terms of size, complexity, and data management. The new inventive concept addresses these limitations by proposing a next-generation system that is more compact, efficient, and data-driven.

Detailed Description of the Inventive Concept

The system comprises a wearable, implantable, or minimally invasive blood treatment device, a blood warming device integrated with a micro-robotic navigation system, and an artificial intelligence-powered blood circuit optimization module. The device utilizes a nano-material-based blood filter, a bio-compatible blood warming device, and a wireless power transfer system for powering the device. The system also features a decentralized, blockchain-based data management system for tracking patient treatment data and a machine learning algorithm to predict and prevent blood treatment complications.

Novelty and Inventive Step

The new claims introduce several novel and non-obvious features, including the integration of micro-robotic navigation, artificial intelligence, and blockchain technology, which significantly improve the efficiency, safety, and data management of extracorporeal blood treatment.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include a modular, 3D-printed blood treatment device, a swarm of micro-robots for cleaning and preparing the blood circuit, and a machine learning algorithm to optimize the priming process based on real-time sensor data.

Potential Commercial Applications and Market

The next-generation extracorporeal blood treatment system has significant commercial potential in the medical device industry, particularly in the areas of cardiovascular disease, oncology, and critical care. The system's compact size, efficiency, and data-driven approach make it an attractive solution for hospitals, clinics, and patients worldwide.

CPC Classifications

SectionClassGroup
A A61 A61M1/369
A A61 A61M1/3623
A A61 A61M1/3626
A A61 A61M1/3627
A A61 A61M1/3643
A A61 A61M39/28
A A61 A61M2205/3344
A A61 A61M2205/36

Original Patent Information

Patent NumberUS 11,857,715
TitleExtracorporeal blood treatment apparatus
Assignee(s)Gambro Lundia AB